BMS 986166Alternative Names: BMS-986166
Latest Information Update: 07 Jun 2016
At a glance
- Originator Bristol-Myers Squibb
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 31 May 2016 Preclinical trials in Undefined indication in USA (PO) before May 2016
- 31 May 2016 Bristol Myers Squibb plans a phase I trial in Healthy volunteers in USA (PO, Liquid) (NCT02790125)